Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053459 | 0.96 | EPHX1 (0.57) | EPHX1THRBATML3MBTL1GAA | |
| SCHEMBL2802318 | 0.94 | EPHX1 (0.60) | EPHX1THRBATML3MBTL1NPSR1 | |
| SCHEMBL8393517 | 0.94 | EPHX1 (0.60) | EPHX1THRBATML3MBTL1NPSR1 | |
| SCHEMBL20350198 | 0.94 | EPHX1 (0.60) | EPHX1THRBATML3MBTL1NPSR1 | |
| Hydrochloric Acid SCHEMBL4535556 | 0.92 | EPHX1 (0.58) | EPHX1THRBATML3MBTL1NPSR1 | |
| SCHEMBL7788916 | 0.91 | SMYD3 (0.47) | EPHX1THRBATML3MBTL1NFKB1 | |
| SCHEMBL7470486 | 0.91 | — | — | |
| SCHEMBL18380884 | 0.91 | SMYD3 (0.47) | EPHX1THRBATML3MBTL1NFKB1 | |
| Hydrochloric Acid SCHEMBL3971132 | 0.89 | SMYD3 (0.46) | EPHX1THRBATML3MBTL1NFKB1 | |
| SCHEMBL8408096 | 0.86 | EPHX1 (0.61) | EPHX1THRBATML3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250011288-A1 | RXFP1 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-01-09 | — | — | US | disclosed |
| EP-4448508-A1 | BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448504-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4284854-A1 | REPROCESSABLE COMPOSITIONS | Massachusetts Institute of Technology (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023114823-A1 | BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114818-A1 | NAPHTHALENE AND QUINOLINE ANALOGS AS RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022164503-A1 | REPROCESSABLE COMPOSITIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2014088519-A1 | COMPOUNDS INCLUDING MAP KINASE INTERACTING KINASES 1 AND 2 (MNK1 AND MNK2) MODULATORS AND ABL AND ABL (T315I) INHIBITORS, AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2014-06-12 | — | — | WO | disclosed |
| US-7589220-B2 | Enzyme inhibitors for anandamide transporter and pharmacological use with urea, amide, thiourea or other groups | UNIVERSITY OF CONNECTICUT (US) | 2009-09-15 | — | — | US | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | RXFP1, RXFP2, RXFP3 | EPHX1 1084/4885THRB 996/4885ATM 3965/4885 |
| US-20250011288-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | EPHX1 1459/4885THRB 345/4885ATM 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.